Europe in vitro diagnostics market size is expected to grow from USD 32 billion in 2024 to USD 34 billion in 2025 and USD 57 billion by 2035, at a CAGR of 5.4%

The Europe In-Vitro Diagnostics Market Report is Segmented by Test Type (Clinical Chemistry, and More), Product & Service (Instrument, and More), Usability (Disposable IVD Devices, and More), Specimen Type (Blood, and More), Site of Testing (Central Laboratories and More), Application (Infectious Diseases and More), End User (Diagnostic Laboratories and More) and Country. The Market Forecasts are Provided in Terms of Value (USD).

Europe In-Vitro Diagnostics Market is projected to reach USD 36.93 billion by 2032, growing at a CAGR of 4.5% from 2024-2032.

According to the latest research report, the Europe in vitro diagnostics market is projected to grow at a CAGR of 4.87% during 2025-2033. The report provides a comprehensive analysis of key trends across market segments, with detailed forecasts at regional and country levels for the period 2024-2032. It categorizes the market based on test type, product, usability, application, and end user.

Europe In Vitro Diagnostics Market Outlook 2031

The Europe in vitro diagnostics market size was USD 15.91 Billion in 2022 and is projected to reach USD 24.26 Billion by 2031 expand at a substantial CAGR 4.8% during the forecast period, 2023–2031. The growth of the market is attributed to the wide prevalence of chronic diseases as well as growing public awareness regarding early detection of life-threatening diseases.



Medical devices, assays, and reagents are key components for in vitro diagnostics (IVD) process, which are used to diagnose a medical condition. Various instruments are also used to analyze tissue samples and bodily fluids obtained from patients and some of the key diagnostic instruments are immunodiagnostics, tissue diagnostics, and molecular diagnostics.

The diagnostics devices are also widely adopted for detecting various infectious diseases and chronic illness such as cardiac disorders, cancer, and diabetes. Furthermore, since the use and handling of in vitro diagnostics necessitates professional experience, diagnosis is carried out in specialist medical facilities using instruments. IVD materials, for example, are used in standalone labs, clinics, and point-of-care settings.



The elderly population is vulnerable to a variety of degenerative and infectious diseases, which is resulting in a wide occurrence of targeted diseases of this group of population. According to a report, the number of people aged 65 and above who are suffering from such diseases in Europe is projected to increase from 18.5 percent in 2014 to 28.7 percent in 2080. Since diagnostic interpretation is required for effective disease treatment, IVDs are important parts of the healthcare industry, especially in the diseases diagnosis.

Europe In Vitro Diagnostics Market Trends, Drivers, Restraints, and Opportunities

• <span style="font-size:12

The Europe in-vitro diagnostics market is expected to grow at a CAGR of 4.20% during the forecast period of 2025-2034, driven by the increasing healthcare needs, the rising development of advanced diagnostic technologies, and regulatory improvements in the region.

The in Vitro Diagnostics Market Report is Segmented by Test Type (Clinical Chemistry, Molecular Diagnostics, and More), Product (Instruments, Reagents and More), Usability (Disposable IVD Devices, Reusable Equipment), Application (Infectious Diseases, Oncology, Cardiology, and More), End User (Stand-Alone Laboratories, and More), Geography (North America, Europe, and More). The Market Forecasts are Provided in Terms of Value (USD).

In the period 2020-2021, Slovakia had the largest growth rate in the European in vitro diagnostics market at almost *** percent. This was followed by a growth of ***** percent in Germany. The IVD market in Germany was already the largest in Europe in 2020 and solidified this position in 2021.

The European In Vitro Diagnostics (IVD) market, valued at approximately €25 billion in 2025, is poised for robust growth, exhibiting a Compound Annual Growth Rate (CAGR) of 5.5% from 2025 to 2033. This expansion is driven by several key factors. Firstly, the increasing prevalence of chronic diseases like diabetes, cancer, and cardiovascular ailments fuels demand for diagnostic testing. Secondly, advancements in molecular diagnostics and the development of more sophisticated, automated IVD instruments contribute significantly to market growth. Technological innovations such as point-of-care testing and rapid diagnostic tests are also streamlining workflows and enhancing diagnostic accuracy, further stimulating demand. Government initiatives promoting preventative healthcare and early disease detection in European nations bolster the market, as does the rise in personalized medicine, demanding highly specific and targeted diagnostic solutions. Finally, the ongoing integration of IVD with healthcare information systems improves data management and facilitates better patient care, adding another layer to market expansion. However, market growth is not without challenges. Regulatory hurdles and reimbursement complexities in different European countries can slow down market penetration for new technologies. Furthermore, the high cost associated with advanced IVD technologies, especially molecular diagnostics, can create access barriers, especially in resource-constrained healthcare settings. Competition amongst established industry giants like Abbott, Roche, and Siemens, alongside the emergence of innovative smaller players, also shapes market dynamics. Despite these restraints, the market's overall growth trajectory remains positive, propelled by demographic changes, increasing healthcare expenditure, and technological advancements making IVD testing more accessible and effective. The segment of molecular diagnostics is anticipated to experience the most rapid growth, driven by increasing demand for faster and more accurate tests for infectious diseases and genetic disorders. Recent developments include: In March 2023, MGI Tech Co., Ltd. received the CE mark for the DNBSeq-G99 sequencer with an aim to precise sequencing of genetic substances., In December 2022, BioMérieux SA received the CE mark for Vidas Kube automated immunoassay system to diagnose immunochemistry, infectious diseases, and food industry pathogens., In September 2022, Noul Co., Ltd. received the CE-IVD mark for two next-generation diagnostic testing products, miLab Cartridge CER and miLab Cartridge BCM to expand its product line in in-vitro diagnostics systems.. Key drivers for this market are: High Prevalence of Chronic Diseases, Increasing Demand for Point-of-care Diagnostics; Technological Advancements in In-Vitro Diagnostics Devices. Potential restraints include: High Prevalence of Chronic Diseases, Increasing Demand for Point-of-care Diagnostics; Technological Advancements in In-Vitro Diagnostics Devices. Notable trends are: The Instrument Segment is Expected to Hold a Major Share in the Market.

Europe In-Vitro Diagnostics Market valued USD 14.89 Bn in 2023, and is projected to hit USD 18.67 Bn by 2030, driven by growing aging population

Snapshot img

In-Vitro Diagnostics Market Size 2025-2029

The in-vitro diagnostics (IVD) market size is forecast to increase by US $28.8 billion, at a CAGR of 4.6% between 2024 and 2029.

Major Market Trends & Insights

North America dominated the market and accounted for a 44% growth during the forecast period.
The market is expected to grow significantly in Europe Region as well over the forecast period.
By the Product Type, the Reagents and kits sub-segment was valued at US $70.30 billion in 2023
By the Technology, the Immunoassay sub-segment accounted for the largest market revenue share in 2023

Market Size & Forecast

Future Opportunities: US $28.8 billion 
CAGR : 4.6%
North America: Largest market in 2023



The market is a dynamic and evolving sector that plays a crucial role in the healthcare industry. This market is driven by various factors, including the increasing global population aging and the rise in chronic and infectious diseases. Advanced treatment solutions are being increasingly adopted to address these health concerns, leading to a growing demand for IVD tests. Stringent regulatory bodies guide IVD manufacturers, ensuring the production and distribution of accurate and reliable diagnostic tools. The market is characterized by continuous innovation, with companies investing heavily in research and development to introduce new and improved products.
According to recent data, the IVD market's growth rate has been steady, with a significant increase in demand for molecular diagnostics and point-of-care testing. In comparison to the previous year, the market has experienced a 23.3% rise in sales of molecular diagnostics. This trend is expected to continue, as these tests offer faster results and increased accuracy compared to traditional methods. The IVD market's dynamics are influenced by various factors, such as technological advancements, regulatory requirements, and market competition. Test accuracy and sensitivity are paramount in IVD, with therapeutic drug monitoring and diagnostic workflow optimization being key areas of focus. Lab-on-a-chip devices and IVD reagents are revolutionizing sample preparation and assay validation processes. Companies are focusing on developing automated and portable diagnostic devices, making testing more accessible and convenient for healthcare providers and patients.
Additionally, regulatory bodies are implementing stricter guidelines to ensure the safety and efficacy of IVD products. Despite these challenges, the IVD market presents significant opportunities for growth, particularly in emerging markets. As the global population ages and the prevalence of chronic and infectious diseases continues to rise, the demand for accurate and reliable diagnostic tools is expected to increase. This trend is likely to be further fueled by advancements in technology and the increasing focus on personalized medicine. In conclusion, the In-Vitro Diagnostics Market is a dynamic and evolving sector that plays a crucial role in the healthcare industry.
Driven by factors such as an aging population, the rise in chronic and infectious diseases, and technological advancements, the market is expected to continue growing steadily in the coming years. Companies are investing heavily in research and development to introduce new and improved products, while regulatory bodies are implementing stricter guidelines to ensure the safety and efficacy of IVD products. Despite challenges, the market presents significant opportunities for growth, particularly in emerging markets.

What will be the Size of the In-Vitro Diagnostics (IVD) Market during the forecast period?

Get Key Insights on Market Forecast (PDF) Request Free Sample

The market encompasses a diverse range of technologies and applications, contributing significantly to the global healthcare industry. The current market share for IVDs is estimated at approximately 20% of the overall diagnostic market, with a notable presence in assay performance, result reporting, and digital PCR. The IVD market demonstrates a steady growth trajectory, with an anticipated expansion of around 7% per annum. This growth is driven by advancements in areas such as sample automation, diagnostic accuracy, and method validation. Comparatively, digital PCR exhibits a higher growth rate, expanding at a pace of approximately 12% per annum.
This technology's superior clinical specificity and performance characteristics have led to its increasing adoption in various clinical applications. Moreover, the ongoing quest for test standardization and quality assurance has resulted in the refinement of calibration methods, such as Mass Spectrometry and microarray technology. These advancements have significantly improved analytical sensitivity and specificity, enabling more accurate and reliable diagnostic results. The false positive rate for IVDs is generally low, typically below 5%, while th

The size of the European In Vitro Diagnostics Market was valued at USD 25.4 billion in 2023 and is projected to reach USD 43.5 billion by 2032, with an expected CAGR of 5.50% during the forecast period. The European In Vitro Diagnostics (IVD) Market refers to the diagnostic tests that are conducted on the biological samples such as blood, organs tissues etc. , for the diagnosis of diseases, identification of health status or to facilitate treatment. Included in the market is molecular diagnostics and imaging, immunoassay, clinical chemistry, and point of care testing among others. Notable trends which are expected to impact this market are molecular diagnostics, personalized medicine, and point of care testing which has been spearheaded by NGS and diagnosis by smart machines. The market is driven by factors such as increasing population, improved healthcare and diagnosis, and increased rate of chronic diseases. Other driving factors consist of regulatory similarity across European nations, rapid boosting in technology and innovations, and a robust health care industry investment as well. Recent developments include: In March 2023, MGI Tech Co., Ltd. received the CE mark for the DNBSeq-G99 sequencer with an aim to precise sequencing of genetic substances., In December 2022, BioMérieux SA received the CE mark for Vidas Kube automated immunoassay system to diagnose immunochemistry, infectious diseases, and food industry pathogens., In September 2022, Noul Co., Ltd. received the CE-IVD mark for two next-generation diagnostic testing products, miLab Cartridge CER and miLab Cartridge BCM to expand its product line in in-vitro diagnostics systems.. Key drivers for this market are: High Prevalence of Chronic Diseases, Increasing Demand for Point-of-care Diagnostics; Technological Advancements in In-Vitro Diagnostics Devices. Potential restraints include: Stringent Regulations, Cumbersome Reimbursement Procedures. Notable trends are: The Instrument Segment is Expected to Hold a Major Share in the Market.

In 2022, the in vitro diagnostics market in Europe shrank by around ** percent, by far the biggest drop since 2009. There was a drop of a further **** percent in the market in 2023. These two years of declining growth followed 2021 in which unprecedented growth of almost ** percent was recorded.

The Europe In-vitro Diagnostics Marketsize was valued at USD 94.67 USD billion in 2023 and is projected to reach USD 153.02 USD billion by 2032, exhibiting a CAGR of 7.1 % during the forecast period.In vitro diagnostics refers to medical exams performed on samples like blood urine or tissues out of doors the frame to diagnose sicknesses infections or conditions those tests encompass diverse technologies inclusive of molecular diagnostics immunoassays clinical chemistry and genetic checking out .IVD performs a pivotal function in healthcare via imparting correct and well timed diagnostic records guiding treatment various check talents and point of care trying out for fast effects . The impact of IVD is profound , improving affected person care thru early disease detection allowing customized medication with genetic and biomarker insights contributing to public fitness surveillance at some stage in outbreaks facilitating clinical research and probably lowering health costs by means of preventing needless remedies IVD is a vital aspect of modern medication improving diagnostics abilties and ultimately reaping benefits affected person effects and healthcare efficiency Key drivers for this market are: Growing Prevalence of Allergies to Augment the Demand for Immunotherapy Drugs. Potential restraints include: Changing Regulatory Environment Creating Operational Barriers May Limit Market Growth . Notable trends are: Increasing Number of Hospitals and ASCs Identified as Significant Market Trend.

In 2021, Germany had the largest in vitro diagnostics (IVD) market size in Europe at over *** billion euros. This was followed by France with a market size of *** billion euros, and Italy at *** billion euros.

The Europe In Vitro Diagnostics Market size was valued at USD 26.77 billion in 2023 and is projected to reach USD 28.11 billion by 2032, exhibiting a CAGR of 0.7 % during the forecasts period. In Vitro Diagnostics (IVD) are medical tests conducted on samples taken from the human body, such as blood or tissue, to detect diseases, conditions, and infections. The term in vitro" indicating that these tests are typically performed outside the living organism in a controlled environment, like test tubes or petri dishes. IVDs are essential tools in healthcare, providing critical information for diagnosis, monitoring, and guiding treatment decisions. IVDs range from simple tests, such as pregnancy tests that can be done at home, to more complex analyses carried out in clinical laboratories. They play a pivotal role in the early detection of diseases, management of chronic conditions, and supporting personalized medicine by identifying patients who may benefit from specific treatments.

In-vitro Diagnostics Market Outlook

According to our latest research, the global in-vitro diagnostics (IVD) market size reached USD 102.6 billion in 2024. The market is currently experiencing robust expansion, supported by a CAGR of 5.4% during the forecast period. By 2033, the in-vitro diagnostics market is projected to attain a value of USD 163.4 billion. This growth is primarily driven by the increasing prevalence of chronic and infectious diseases worldwide, ongoing technological advancements in diagnostic tools, and the rising emphasis on early disease detection and personalized medicine.

One of the most significant growth drivers for the in-vitro diagnostics market is the rising global burden of chronic and infectious diseases. The increasing incidence of conditions such as diabetes, cancer, cardiovascular diseases, and infectious diseases like tuberculosis and HIV has heightened the demand for early and accurate diagnostic solutions. Early diagnosis is crucial for effective disease management, leading to improved patient outcomes and reduced healthcare costs. Additionally, the emergence of new infectious threats and pandemics, as witnessed during the COVID-19 crisis, has further underscored the vital role of IVD in rapid screening and disease surveillance, prompting both public and private sectors to invest heavily in diagnostic infrastructure and innovation.

Technological advancements are another key factor propelling the growth of the in-vitro diagnostics market. The integration of cutting-edge technologies such as next-generation sequencing, digital PCR, microfluidics, and artificial intelligence has revolutionized the field of diagnostics. These innovations have enabled higher sensitivity, specificity, and automation in testing, thereby enhancing laboratory efficiency and accuracy. Moreover, the increasing adoption of point-of-care testing (POCT) devices and home-based diagnostic solutions is making healthcare more accessible and patient-centric. The development of multiplex assays and companion diagnostics is also supporting the trend towards personalized medicine, allowing for tailored treatment regimens based on individual patient profiles.

Another important growth factor is the supportive regulatory landscape and increasing healthcare expenditure globally. Governments and regulatory bodies are streamlining approval processes for novel diagnostic products, ensuring faster access to advanced testing solutions. Furthermore, rising investments by public and private entities in healthcare infrastructure, particularly in emerging economies, are expanding the reach of IVD technologies. Initiatives aimed at strengthening laboratory networks, improving disease surveillance, and enhancing quality assurance are fostering market growth. The growing awareness among patients and healthcare professionals about the benefits of early detection and preventive care is also contributing to the increased adoption of IVD products.

From a regional perspective, North America continues to dominate the in-vitro diagnostics market, accounting for the largest share in 2024, followed by Europe and Asia Pacific. The region’s leadership is attributed to the presence of advanced healthcare systems, high adoption rates of innovative diagnostic technologies, and significant investments in research and development. However, Asia Pacific is expected to exhibit the fastest growth rate during the forecast period, driven by rising healthcare awareness, expanding patient population, and increasing government initiatives to improve diagnostic infrastructure. Latin America and the Middle East & Africa are also witnessing steady growth, supported by improving healthcare access and rising investments in laboratory services.

Product Type Analysis

The in-vitro diagnostics market by product type is segmented into Instruments, Reagents & Kits, and Software & Services. Among these, reagents & kits represent the largest revenue contributor in 2024, owing to their recurring usage in a wide range of diagnostic tests across var

Europe In Vitro Diagnostics (IVD) Market size was valued at USD 16.45 Billion in 2024 and is projected to reach USD 24.72 Billion by 2032, growing at a CAGR of 5.3% from 2026 to 2032.

Key Market Drivers:

Increasing Incidence of Chronic Diseases: The increased prevalence of chronic diseases such as diabetes, cancer, and cardiovascular disease is a significant driver of the IVD industry. According to the European Commission's 2020 report, around 60% of adults in the EU have at least one chronic condition. As these diseases require continuous monitoring and management, the demand for in vitro diagnostic testing continues to grow, driving market expansion.

Technological Advancements in IVD Devices: The increased use of advanced technologies, such as molecular diagnostics and point-of-care testing (POCT), is driving the IVD market in Europe.

In 2021, Germany had by far the largest share of the in vitro diagnostics market in Europe. At over ** percent, Germany's share of the IVD market was more than double the next highest share, which was France at **** percent.

In 2029, the global in vitro diagnostics market is forecast to have revenue of over ***** billion U.S. dollars. Between 2020 and 2021, the IVD market size increased significantly, going from around ** billion U.S. dollars to just under 100 billion U.S. dollars. Market leaders and regional distribution Swiss-based pharmaceutical company Roche has maintained its position as the global leader in the IVD market, with projected revenues exceeding ** billion U.S. dollars by 2024. Other major players include Abbott Laboratories and Danaher from the United States. In Europe, Germany dominates the IVD market with a ** percent share, more than double that of France, the next largest market at **** percent. Market composition The IVD market comprises various product categories, including reagents, instruments, and software services. Consumable products accounted for the largest share of the IVD market globally, representing around ** percent of the total market.